AbbVie booth at AACR 2026
Biotech

AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’

AbbVie scrapped a phase 2 solid tumor drug after deciding the antibody was unlikely to best current standard of care, Fierce has learned.
James Waldron Nov 3, 2026 8:38am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
Pfizer

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Nov 3, 2026 8:02am
Close-up of shredded document

Novartis scraps $800M BioArctic brain collab after barely a year

Nov 3, 2026 4:53am
Money present

Rhythm drums up LG obesity license to as much as $855M

Nov 3, 2026 9:32am
un1Qure Genezen

FDA grants uniQure priority review of its Huntington’s drug

Nov 2, 2026 4:12pm
More News
Fierce Pharma

Karyopharm files Chapter 11 ahead of Ayrmid merger

Nov 2, 2026 10:46am

Teva ends trial of one of original line-up of innovative meds

Nov 2, 2026 9:22am

Bright Minds seizure study on partial hold over toxicity in mice

Nov 2, 2026 8:43am

Lower dose of Tiziana CD3 drug hits MS goal, unlike higher dose

Nov 2, 2026 8:37am